About: GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.19 (-6.25%)
GOVX NASDAQ GeoVax Labs Inc
GeoVax Labs Inc share price
Atividade de preço de GOVX
Último preço
$ 0,190
Variação (24h)
-0,01 USD (6,25%)
Volume
146.27K
Volume (média 4 sem.)
-
Abertura
$ 0,19
Variação do dia
$ 0,18 - $ 0,20
Fechamento anterior
$ 0,20
Último negócio
29 Oct, 8:05 pm GMT+0
Atrasado
29 Oct, 8:05 pm GMT+0
GOVX price performance
Atrasado
29 Oct, 8:05 pm GMT+0
quote.marketSignals